New Insights in Lipid Metabolism: Potential Therapeutic Targets for the Treatment of Alzheimer's Disease

Overview

Journal Front Neurosci

Date 2024 Sep 26

PMID 39323915

Authors

Yuan Cao

Lin-Wei Zhao

Zi-Xin Chen

Shao-Hua Li

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is increasingly recognized as being intertwined with the dysregulation of lipid metabolism. Lipids are a significant class of nutrients vital to all organisms, playing crucial roles in cellular structure, energy storage, and signaling. Alterations in the levels of various lipids in AD brains and dysregulation of lipid pathways and transportation have been implicated in AD pathogenesis. Clinically, evidence for a high-fat diet firmly links disrupted lipid metabolism to the pathogenesis and progression of AD, although contradictory findings warrant further exploration. In view of the significance of various lipids in brain physiology, the discovery of complex and diverse mechanisms that connect lipid metabolism with AD-related pathophysiology will bring new hope for patients with AD, underscoring the importance of lipid metabolism in AD pathophysiology, and promising targets for therapeutic intervention. Specifically, cholesterol, sphingolipids, and fatty acids have been shown to influence amyloid-beta (Aβ) accumulation and tau hyperphosphorylation, which are hallmarks of AD pathology. Recent studies have highlighted the potential therapeutic targets within lipid metabolism, such as enhancing apolipoprotein E lipidation, activating liver X receptors and retinoid X receptors, and modulating peroxisome proliferator-activated receptors. Ongoing clinical trials are investigating the efficacy of these strategies, including the use of ketogenic diets, statin therapy, and novel compounds like NE3107. The implications of these findings suggest that targeting lipid metabolism could offer new avenues for the treatment and management of AD. By concentrating on alterations in lipid metabolism within the central nervous system and their contribution to AD development, this review aims to shed light on novel research directions and treatment approaches for combating AD, offering hope for the development of more effective management strategies.

Citing Articles

Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.

Ortiz-Islas E, Montes P, Rodriguez-Perez C, Ruiz-Sanchez E, Sanchez-Barbosa T, Pichardo-Rojas D Pharmaceutics. 2025; 17(1).

PMID: 39861773 PMC: 11768419. DOI: 10.3390/pharmaceutics17010128.

Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes.

Yanai H, Adachi H, Hakoshima M, Katsuyama H Molecules. 2025; 29(24.

PMID: 39770025 PMC: 11677283. DOI: 10.3390/molecules29245936.

References

Sanan D, Weisgraber K, Russell S, Mahley R, Huang D, Saunders A . Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994; 94(2):860-9. PMC: 296168. DOI: 10.1172/JCI117407. View

Kawarabayashi T, Shoji M, Younkin L, Wen-Lang L, Dickson D, Murakami T . Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2004; 24(15):3801-9. PMC: 6729359. DOI: 10.1523/JNEUROSCI.5543-03.2004. View

Kimoto A, Ohnuma T, Toda A, Takebayashi Y, Higashiyama R, Tagata Y . Medium-chain triglycerides given in the early stage of mild-to-moderate Alzheimer's disease enhance memory function. Psychogeriatrics. 2017; 17(6):520-521. DOI: 10.1111/psyg.12257. View

Sastry P . Lipids of nervous tissue: composition and metabolism. Prog Lipid Res. 1985; 24(2):69-176. DOI: 10.1016/0163-7827(85)90011-6. View

De Roeck A, Van Broeckhoven C, Sleegers K . The role of ABCA7 in Alzheimer's disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019; 138(2):201-220. PMC: 6660495. DOI: 10.1007/s00401-019-01994-1. View

Bellenguez C, Kucukali F, Jansen I, Kleineidam L, Moreno-Grau S, Amin N . New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022; 54(4):412-436. PMC: 9005347. DOI: 10.1038/s41588-022-01024-z. View

Cai D, Zhong M, Wang R, Netzer W, Shields D, Zheng H . Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A. 2006; 103(6):1936-40. PMC: 1413666. DOI: 10.1073/pnas.0510710103. View

Gibson G, Haroutunian V, Zhang H, PARK L, Shi Q, Lesser M . Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol. 2000; 48(3):297-303. View

Segarra M, Aburto M, Acker-Palmer A . Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis. Trends Neurosci. 2021; 44(5):393-405. DOI: 10.1016/j.tins.2020.12.002. View

10.

Mahley R . Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med (Berl). 2016; 94(7):739-46. PMC: 4921111. DOI: 10.1007/s00109-016-1427-y. View

11.

Tai L, Koster K, Luo J, Lee S, Wang Y, Collins N . Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014; 289(44):30538-30555. PMC: 4215234. DOI: 10.1074/jbc.M114.600833. View

12.

Miller Y, Navia-Pelaez J, Corr M, Yaksh T . Lipid rafts in glial cells: role in neuroinflammation and pain processing. J Lipid Res. 2019; 61(5):655-666. PMC: 7193960. DOI: 10.1194/jlr.TR119000468. View

13.

Broom G, Shaw I, Rucklidge J . The ketogenic diet as a potential treatment and prevention strategy for Alzheimer's disease. Nutrition. 2018; 60:118-121. DOI: 10.1016/j.nut.2018.10.003. View

14.

Kracun I, Rosner H, Drnovsek V, Heffer-Lauc M, Cosovic C, Lauc G . Human brain gangliosides in development, aging and disease. Int J Dev Biol. 1991; 35(3):289-95. View

15.

Xiu J, Nordberg A, Qi X, Guan Z . Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem Int. 2006; 49(5):459-65. DOI: 10.1016/j.neuint.2006.03.007. View

16.

Naudi A, Cabre R, Jove M, Ayala V, Gonzalo H, Portero-Otin M . Lipidomics of human brain aging and Alzheimer's disease pathology. Int Rev Neurobiol. 2015; 122:133-89. DOI: 10.1016/bs.irn.2015.05.008. View

17.

Liu Q, Trotter J, Zhang J, Peters M, Cheng H, Bao J . Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci. 2010; 30(50):17068-78. PMC: 3146802. DOI: 10.1523/JNEUROSCI.4067-10.2010. View

18.

Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A . Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus. 2010; 22(5):1040-50. DOI: 10.1002/hipo.20883. View

19.

Ghosh S, Swerdlow R, Miller S, Sheeman B, Parker Jr W, Davis R . Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann N Y Acad Sci. 2000; 893:176-91. DOI: 10.1111/j.1749-6632.1999.tb07825.x. View

20.

Paolo G, Kim T . Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci. 2011; 12(5):284-96. PMC: 3321383. DOI: 10.1038/nrn3012. View